Combined Association of Novel and Traditional Inflammatory Biomarkers With Carotid Artery Plaque: GlycA Versus C-Reactive Protein (ELSA-Brasil)

Imagem de Miniatura
Arquivos
art_TEBAR_Combined_Association_of_Novel_and_Traditional_Inflammatory_Biomarkers_2023.PDF (427.69 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
Autores
BLAHA, Michael J.
JONES, Steven R.
Citação
AMERICAN JOURNAL OF CARDIOLOGY, v.204, p.140-150, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Elevated levels of glycoprotein acetylation (GlycA) and C-reactive protein (CRP) have been associated with carotid artery plaque (CAP). However, it is not yet established if elevations in both inflammatory biomarkers provide incremental association with CAP. This study aimed evaluate the cross-sectional association of high CRP and GlycA with CAP at baseline participants from the ELSA-Brasil adult cohort. Participants with information on CRP, GlycA, and CAP with neither previous cardiovascular disease nor CRP >10 mg/ L were included. High GlycA and CRP were defined as values within upper quintile and >3 mg/L, respectively. Participants were classified into 4 groups: 1. nonelevated CRP/ GlycA (reference group); 2. elevated CRP alone; 3. elevated GlycA alone; and 4. both elevated. The analysis included 4,126 participants with median age of 50 years-old, being 54.2% of women. Prevalence of CAP was 36.1%. Participants with high CRP had the highest frequency of obesity, whereas participants with high GlycA presented higher cardiovascular risk factor burden and were more likely to have CAP than the reference group (odds ratio [OR] 1.39, 95% confidence interval [CI] 1.11 to 1.73), persisting after multivariable adjustment (OR 1.37, 95% CI 1.02 to 1.83). Participants with both elevated CRP and GlycA were more likely to have CAP in crude (OR 1.35, 95% CI 1.10 to 1.65) but not in adjusted models. The findings suggest potential different biologic pathways between inflammation and carotid atherosclerosis: high GlycA was associated with CAP whereas high CRP was more associated with obesity. & COPY; 2023 Elsevier Inc. All rights reserved. (Am J Cardiol 2023;204:140-150)
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/55958
Referências
  1. Ammirati E, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/718329
  2. Andersen K, 2022, LAEKNABLADID, V108, P346, DOI 10.17992/lbl.2022.0708.701
  3. Aquino EML, 2013, REV SAUDE PUBL, V47, P10, DOI 10.1590/S0034-8910.2013047003953
  4. Aquino EML, 2012, AM J EPIDEMIOL, V175, P315, DOI 10.1093/aje/kwr294
  5. Aronson D, 2004, INT J OBESITY, V28, P674, DOI 10.1038/sj.ijo.0802609
  6. Asher Jordan, 2007, J Clin Hypertens (Greenwich), V9, P622, DOI 10.1111/j.1524-6175.2007.06639.x
  7. Bensenor IM, 2013, REV SAUDE PUBL, V47, P37, DOI 10.1590/S0034-8910.2013047003780
  8. Benson EMA, 2018, CLIN CARDIOL, V41, P1439, DOI 10.1002/clc.23069
  9. Neto JAC, 2015, CIENC SAUDE COLETIVA, V20, P1909, DOI 10.1590/1413-81232015206.17212014
  10. Chiesa ST, 2022, J AM HEART ASSOC, V11, DOI 10.1161/JAHA.121.024380
  11. Chor D, 2013, REV SAUDE PUBL, V47, P27, DOI 10.1590/S0034-8910.2013047003835
  12. Christen T, 2019, NUTR METAB CARDIOVAS, V29, P728, DOI 10.1016/j.numecd.2019.03.010
  13. Connelly MA, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1321-6
  14. Din-Dzietham R, 2004, AM J HYPERTENS, V17, P304, DOI 10.1016/j.amjhyper.2003.12.004
  15. Duprez DA, 2016, CLIN CHEM, V62, P1020, DOI 10.1373/clinchem.2016.255828
  16. Eltoft A, 2017, ATHEROSCLEROSIS, V263, P293, DOI 10.1016/j.atherosclerosis.2017.07.001
  17. Falk E, 2006, J AM COLL CARDIOL, V47, pC7, DOI 10.1016/j.jacc.2005.09.068
  18. Fashanu OE, 2019, ANGIOLOGY, V70, P737, DOI 10.1177/0003319719845185
  19. Fedeli LG, 2013, REV SAUDE PUBL, V47, P63, DOI 10.1590/S0034-8910.2013047003807
  20. FERARD G, 1980, CLIN CHEM, V26, P782
  21. Fischer K, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001606
  22. Frostegård J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-117
  23. Gatto L, 2020, EUR HEART J SUPPL, V22, pE87, DOI 10.1093/eurheartj/suaa068
  24. Gepner AD, 2015, CIRC-CARDIOVASC IMAG, V8, DOI 10.1161/CIRCIMAGING.114.002262
  25. Gruppen EG, 2019, CLIN CHIM ACTA, V488, P7, DOI 10.1016/j.cca.2018.10.029
  26. Gruppen EG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139057
  27. Hage FG, 2007, J AM COLL CARDIOL, V50, P1115, DOI 10.1016/j.jacc.2007.06.012
  28. Hallal PC, 2004, MED SCI SPORT EXER, V36, P556, DOI 10.1249/01.MSS.0000117161.66394.07
  29. Huang XY, 2016, ATHEROSCLEROSIS, V246, P44, DOI 10.1016/j.atherosclerosis.2015.12.024
  30. Ji X, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.10.115
  31. Lal BK, 2021, STROKE, V52, P2053, DOI 10.1161/STROKEAHA.120.032723
  32. Lawler PR, 2016, CIRC RES, V118, P1106, DOI 10.1161/CIRCRESAHA.115.308078
  33. Levine JA, 2020, J CLIN LIPIDOL, V14, P667, DOI 10.1016/j.jacl.2020.07.012
  34. Li J, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.642192
  35. Li YW, 2017, ATHEROSCLEROSIS, V259, P75, DOI 10.1016/j.atherosclerosis.2017.02.003
  36. McGarrah RW, 2017, CLIN CHEM, V63, P288, DOI 10.1373/clinchem.2016.261636
  37. Mehta NN, 2020, AM J PREVENT CARDIOL, V4, DOI 10.1016/j.ajpc.2020.100120
  38. Mill JG, 2013, REV SAUDE PUBL, V47, P54, DOI 10.1590/S0034-8910.2013047003851
  39. Nambi V, 2010, J AM COLL CARDIOL, V55, P1600, DOI 10.1016/j.jacc.2009.11.075
  40. Nascimento LR, 2013, REV SAUDE PUBL, V47, P113, DOI 10.1590/S0034-8910.2013047003825
  41. Nordestgaard BG, 2009, CURR OPIN LIPIDOL, V20, P393, DOI 10.1097/MOL.0b013e3283307bfe
  42. Ojima S, 2020, HYPERTENS RES, V43, P422, DOI 10.1038/s41440-019-0388-2
  43. Otvos JD, 2015, CLIN CHEM, V61, P714, DOI 10.1373/clinchem.2014.232918
  44. Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45
  45. Peters SAE, 2011, J ATHEROSCLER THROMB, V18, P784, DOI 10.5551/jat.8169
  46. Polak JF, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000087
  47. Riggs KA, 2022, AM J PREVENT CARDIOL, V12, DOI 10.1016/j.ajpc.2022.100373
  48. Ritchie SC, 2015, CELL SYST, V1, P293, DOI 10.1016/j.cels.2015.09.007
  49. Santos IS, 2015, ARTERIOSCL THROM VAS, V35, P2054, DOI 10.1161/ATVBAHA.115.305765
  50. Santos RD, 2016, J CLIN LIPIDOL, V10, P1362, DOI 10.1016/j.jacl.2016.08.008
  51. Santos-Neto PJ, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414-431X20198711, 10.1590/1414-431x20198711]
  52. Schmidt MI, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-123
  53. Singh T, 2011, AGEING RES REV, V10, P319, DOI 10.1016/j.arr.2010.11.002
  54. Spagnoli LG, 2007, J NUCL MED, V48, P1800, DOI 10.2967/jnumed.107.038661
  55. Tesauro M, 2017, J INTERN MED, V281, P471, DOI 10.1111/joim.12605
  56. Titan SM, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0779-z
  57. Touboul PJ, 2012, CEREBROVASC DIS, V34, P290, DOI 10.1159/000343145
  58. Wang XJ, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.008701
  59. who, OBESITY
  60. World Health Organization, GLOB REC PHYS ACT HL
  61. Xu RY, 2019, STROKE, V50, P1655, DOI [10.1161/STROKEAHA.119.025101, 10.1161/strokeaha.119.025101]

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - HU
Artigos e Materiais de Revistas Científicas - LIM/13
Artigos e Materiais de Revistas Científicas - LIM/20
Carregar mais